Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
Bolni Marius NagaloYumei ZhouEmilien J LoeuillardChelsae DumbauldOumar BarroNatalie M ElliottAlexander T BakerMansi AroraJames M BogenbergerNathalie MeuriceJoachim PetitPedro Luiz Serrano UsÓn JuniorFaaiq AslamElizabeth RaupachMusa GabereAlexei BasnakianCamila C SimoesMartin J CannonSteven R PostKenneth BuetowJean Christopher ChamcheuMichael T BarrettDan G DudaBertram JacobsRichard VileMichael A BarryLewis R RobertsSumera Irie IlyasMitesh J BoradPublished in: Hepatology (Baltimore, Md.) (2022)
Our findings indicate that wild-type MORV is safe and can induce potent tumor regression via immune-mediated and immune-independent mechanisms in HCC and CCA animal models without dose limiting adverse events. These data warrant further development and clinical translation of MORV as an oncolytic virotherapy platform.